Company profilePharmaceutical#1083 of 1,318 in Pakistan✓ No DRAP alerts

Lucky Core Industries Limited DSL: 013

Pharmaceutical company · 2 brands · 4 molecules

Ranked #6 of 22 companies in Endocrine Hormone Therapy

2 registered products 4 pharmaceutical brands 4 distinct molecules 0 DRAP alerts

Company overview

2
registered products
4
pharmaceutical brands
4
distinct molecules
2
therapeutic classes
0
DRAP alerts

Lucky Core Industries Limited DSL: 013 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 2 product registrations across 4 distinct molecules. Its portfolio is concentrated in Endocrine Hormone Therapy and Cancer. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Anastrozole ...... 1 Mg1 brand
Bicalutamide ...... 50 Mg1 brand

Therapeutic classes

Endocrine Hormone Therapy · 2Cancer · 1

Conditions treated

Oncology · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official2 products · Rs 13,136.02 – Rs 23,223.82
DVAGO2 products · Rs 6,239.66 – Rs 19,991.44
Servaid1 products · Rs 15,177.68 – Rs 15,177.68
Median across source: Rs 15,177.68

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL2 shared molecules
Pharmasol (Pvt) Ltd.2 shared molecules
IRZA PHARMA (PVT) LTD.2 shared molecules
Regal Pharmaceuticals2 shared molecules
EPHARM LABORATORIES2 shared molecules
AJ Mirza Pharma Pvt Ltd2 shared molecules

Get the full profile for Lucky

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.